Skip to main content

ChromoCure, GRG Ink Cancer Treatment Monitoring Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ChromoCure today said that it will collaborate with Genome Research Group in developing technologies for monitoring and determining the efficacy of cancer treatments.

Under the agreement, ChromoCure said that it will have access to GRG's therapeutic modeling protocols and algorithms that use hypothermic modulation and resonance for the non-toxic and non-invasive treatment of cancer. In return, GRG will have access to ChromoCure's chromosomal scanner technology, which includes a series of systems, processes, cell preparation techniques, and diagnostic algorithms.

ChromoCure's systems measure aneuploidy to detect cancer and measure cancer progression. The Reno, Nev.-based firm claims that its scanner is has a 100 percent accuracy rate.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.